Satellos Bioscience (MSLE) Income from Continuing Operations (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Income from Continuing Operations of 9702000.0 for Q1 2026, down 261.3% year-over-year from 6015000.0 in Q1 2025, and down 261.3% quarter-over-quarter from 6015000.0 in Q1 2025.
Satellos Bioscience (MSLE) Income from Continuing Operations (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Income from Continuing Operations for 2 consecutive years, with 9702000.0 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Satellos Bioscience | 206.75 Mn | 206.75 Mn | - | -11.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70 Mn |
| Mar 31, 2025 | 6.02 Mn |